Patents by Inventor Brian W. Budzik

Brian W. Budzik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200261411
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 20, 2020
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Linda S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jaclyn R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
  • Publication number: 20200222540
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 10590077
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian W. Budzik, Brian Griffin Lawhorn, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, David J. Behm
  • Patent number: 10588891
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
  • Publication number: 20200071310
    Abstract: The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 5, 2020
    Inventors: Brian W. BUDZIK, Peng LI, Joseph E. PERO, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, David NORTON, Hendrika Maria Gerarda WILLEMS, Alison Jo-Anne WOOLFORD
  • Patent number: 10576155
    Abstract: The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: March 3, 2020
    Assignee: SIRNA THEREAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Publication number: 20200031820
    Abstract: The present invention relates to 3-carboxylic acid pyrrole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: December 11, 2017
    Publication date: January 30, 2020
    Inventors: Brian W. BUDZIK, Peng LI, Joseph E. PERO, Charl mARY GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Dvid NORTON, Hendrika Maria WILLEMS, Alison Jo-Anne WOOLFORD
  • Publication number: 20190216774
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 18, 2019
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Lisa S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jacyln R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
  • Publication number: 20190202784
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 4, 2019
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian W. BUDZIK, Brian Griffin LAWHORN, Jay M. MATTHEWS, John Jeffrey McATEE, Joseh E. PERO, David J. BEHM
  • Publication number: 20180000939
    Abstract: The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: May 10, 2017
    Publication date: January 4, 2018
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 9669097
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 6, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 9643916
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 9, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. Budzik, Steven L. Colletti, Jennifer R. Davis, Ivory D. Hills, Darla Danile Seifried, Matthew G. Stanton
  • Patent number: 9604908
    Abstract: Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 28, 2017
    Assignee: Sima Therapeutics, Inc.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Steven L. Colletti
  • Publication number: 20170050917
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 23, 2017
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. BUDZIK, Steven L. COLLETTI, Jennifer R. DAVIS, Ivory D. HILLS, Darla Danile SEIFRIED, Matthew G. STANTON
  • Publication number: 20170001947
    Abstract: Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: September 19, 2016
    Publication date: January 5, 2017
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. STANTON, Brian W. BUDZIK, Steven L. COLLETTI
  • Patent number: 9446132
    Abstract: Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: September 20, 2016
    Assignee: Sima Therapeutics, Inc.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Steven L. Colletti
  • Patent number: 9315437
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: April 19, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Brian W. Budzik, Steven L. Colletti, Jennifer R. Davis, Ivory D. Hills, Darla Danile Seifried, Matthew G. Stanton
  • Publication number: 20150315112
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 5, 2015
    Inventors: Brian W. BUDZIK, Steven L. COLLETTI, Jennifer R. DAVIS, Ivory D. HILLS, Darla Danile SEIFRIED, Matthew G. STANTON
  • Patent number: 9062021
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: June 23, 2015
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. Budzik, Steven L. Colletti, Jennifer R. Davis, Ivory D. Hills, Darla Danile Seifried, Matthew G. Stanton
  • Patent number: 9044512
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is more efficacious than traditional cationic lipids. The present invention employs amino alcohols to enhance the efficiency of in vivo delivery of siRNA.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: June 2, 2015
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. Budzik, Steven L. Colletti, Darla Danile Seifried, Matthew G. Stanton, Lu Tian